Eli Lilly and Company (LLY)

Investment Committee Summary

Investment Thesis

At $1,247 on 25 August 2026, the market pays roughly 34 times forward earnings for Lilly, a large multiple of the level at which the mature large-pharma peer group trades. Spot therefore prices sustained franchise compounding and a durable incretin lead, not a cash-cow pharmaceutical. The engine is more cautious. Triangulated fair value of $977 is a gap of -22% to the quote, the probability-weighted expected value is $1,100 and the twelve-month target is $1,126; the shares are trading rich to the weighted anchors, and the SELL follows. The independent cross-checks pull the same way: both the discounted-cash-flow anchor and the peer-multiple read land under the tape. The single biopharma segment carries an operating margin near 51% on a modest base growth assumption, so the premium the engine can justify lives in the multiple rather than in a heroic earnings path — and the overwhelming majority of simulated dispersion is that multiple, which is the honest tell that the position is a bet on the re-rating holding. The single most damaging risk is the manufacturing build: capacity being installed at several times the current depreciation charge only pays if incretin volume keeps compounding, and it is funded against net debt of ~$38.2B.

Narrative drafted 2026-08-16 by claude-opus-5 under supervision; reviewed by Marinus 2026-08-16.

The dashboard below is the whole argument on one page: spot ($1,247) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The highest-probability bear leg is the structural patent-cliff and pricing-erosion state, the heaviest of the downside weights. The mechanism is concrete. Incretin is now the earnings engine, and it faces credible oral and injectable competition alongside government price negotiation on the legacy base. If share slips while negotiated prices step down, revenue can roll over even as unit demand stays firm. The capacity build then de-levers: a fixed manufacturing base carries lower throughput, so the operating margin compresses materially from the level near 51% the base case assumes. A market that paid a premium for compounding re-rates toward the mature-pharma multiple, and net debt of ~$38.2B leaves less room to buy the gap back with repurchases. Earnings and the multiple fall together, and the structural target sits below the 52-week low by construction.

Key Debate

P/E Multiple explains 86% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.

What the Market Is Pricing In

At the current price, the market pays 34.0× consensus forward EPS, vs the house DCF terminal 26.0×, and a peer median 15.0×. The house DCF sits 30% below spot, so the market is pricing in more than the house case — roughly 3.2pp of revenue CAGR.

Variant perception: the house view is below-consensus, and the thesis is primarily event-driven.

Scenario Analysis

The scenario tree spans a structural 'Structural — Patent Cliff (LOE) / IRA Pricing Erosion' downside ($494) to a 'Bull — Blockbuster / Pipeline Re-Rate' bull case ($1,885); the probability-weighted blend (PWEV $1,100) is -12% versus spot.

Share-count charge: none applied. The probability-weighted value above is the gross per-share figure — no annual dilution is deducted — stock-based compensation runs at 0.9% of revenue; free cash flow net of SBC is $8.35B. SBC is therefore disclosed, not charged: read the per-share figures as before dilution.

Scenario rationale — the driver path behind every target:

• Structural — Patent Cliff (LOE) / IRA Pricing Erosion (20%, $494). Structural impairment — patent cliff (LOE) / IRA pricing erosion: earnings AND the multiple compress together. Target sits below the 52-week low by construction.
• Pipeline Setback / Pricing Pressure (17%, $846). Cyclical downturn — drug pricing (IRA) + patent-cliff (LOE) exposure + pipeline/launch trajectory weakens for 1–2 years before normalising.
• Base — Pipeline Offsets LOE (35%, $1,160). Mid-cycle — normalised drug pricing (IRA) + patent-cliff (LOE) exposure + pipeline/launch trajectory; disciplined capital allocation; steady returns.
• Growth — Launch / Indication Expansion (20%, $1,505). Upside — pipeline launches + indication expansion lifts earnings above mid-cycle; the multiple expands modestly.
• Bull — Blockbuster / Pipeline Re-Rate (8%, $1,885). Upside tail — sustained tight conditions or a structural re-rate on pipeline launches + indication expansion.

Valuation Triangulation

Three weighted anchors — an intrinsic dcf, a scenario-weighted pwev and a monte carlo median (student-t + regime switching) — read them with their basis in mind. The Monte Carlo, the DCF terminal and any peer re-rate key off a market multiple, so they are not fully independent; only discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat three numbers as three independent votes.

The house blend DECLARES five anchor weights — DCF 35%, scenario PWEV 25%, Monte Carlo 15%, sum-of-parts 15%, peer re-rate 10%. For this name sum-of-parts, peer P/E re-rate are not computed, so 25% of the declared weight is redistributed across the anchors that exist — which is why the weights above differ from the declared ones. The fair value is unaffected by this disclosure; the blend has always worked this way.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

Monte Carlo — the outcome distribution

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $1,017 and 27% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (86% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 8.5%, 26.0x terminal FCF multiple → $871. This anchor is deliberately the heaviest (47%): it is the valuation least hostage to the current multiple regime.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median EV/Revenue multiple implies $297; the peer-median forward P/E is 15.0x, but the engine carries no P/E-implied price for this name (no forward-EPS basis at the peer step). A premium is only justified by superior growth/margins; otherwise it is multiple risk. Excluded from the weighted blend — shown only as a market cross-check.

Across all anchors the spread is 79% of the median — wide (genuine disagreement — the blend carries low valuation confidence).

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Biopharma multiple (AI re-rating) (base 31.0x)

Peer Quality & Weighting

Quality-weighted forward P/E: 18.1× (simple median 15.0×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $619–$1,280, centre $890 (-29% vs spot); spot sits at the 95th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

That ratio compares triangulated upside against the probability-weighted bear target, not the extreme tail; with a leg missing it is withheld rather than computed from a magnitude. Bull case (Bull — Blockbuster / Pipeline Re-Rate): $1,885.

Company Overview & Business Model

Eli Lilly and Company — HEALTHCARE · DRUG MANUFACTURERS - GENERAL. Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

How it makes money.

Edge. Wide moat — Lilly's moat is patent-protected incretin franchises (tirzepatide) plus manufacturing scale in a supply-constrained GLP-1 market and a deep obesity/diabetes pipeline — a genuinely wide but time-limited moat, since patents expire. The ~33x multiple prices durable mid-teens compounding; that terminal multiple is only justified if next-gen assets (oral GLP-1, amylin combos) refill the moat before LOE. Falsifiable: if a pivotal next-gen readout fails or an oral incretin competitor takes share, the wide-but-fading moat argues for terminal compression toward the ~15x mature-pharma peer median.

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Balance Sheet & Liquidity

Balance-sheet data as of 2025-12-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 1% of revenue; cash conversion (OCF/NI) 82% — cash-backed.

Competitive Moat

Moat sources:

• Patent-protected tirzepatide (Mounjaro/Zepbound) incretin franchise
• GLP-1 manufacturing capacity scarcity as a near-term barrier
• Deep incretin/obesity pipeline (orforglipron oral, retatrutide, amylin)
• Moat is time-limited — patent expiry means terminal durability is not assured

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q2): management +0.33 vs analyst floor +0.02 → delta +0.31 (n=39 mgmt / 13 Q&A; 29th pctile across the S&P book, z -0.6).

Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.

News (last 365d, 1997 articles): avg ticker sentiment +0.23 (bullish 18% / bearish 1%)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Catalyst Calendar

• 2026-09-30 (~37d) — Oral GLP-1 (orforglipron) pivotal / regulatory-filing readout (authored)
• 2026-11-12 (~80d) — GLP-1 manufacturing-capacity expansion online milestone (authored)
• 2027-01-15 (~144d) — IRA Medicare price-negotiation inclusion / drug-list update (authored)

Forecast Track Record

• EPS surprise: beat 75% of the last 8 quarters; average surprise +10.5%.
• Prior-forecast backtest (12 snapshots, 2026-06-27→2026-08-20): directional hit-rate 8%; mean predicted -5.0% vs realised +5.2%. Disconfirming track record is reported, not suppressed.

Catalyst Timeline

6 catalysts in the next 90 days (of 15 tracked). Importance 1–3; confidence 0–1.

_Sources: extended.catalysts, data/catalysts/.json, data/catalysts/macro.json, AV DIVIDENDS, opex 3rd-Friday calc.

Regulatory & Legal Risk

Probabilities and sensitivities are analyst estimates, not market-implied.

Scenario Macro & Key Risks

Decision Rules (Machine-Checked)

Stance: Hold — 0 bullish / 0 bearish / 0 caution rules triggered of 6 evaluable (0 lacked data).

Machine-checked rules over disclosed inputs. The authored falsification triggers elsewhere in this report are analyst judgment and are NOT evaluated here. The stance is a portfolio-management signal and does not modify the published research rating.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Total revenue year-on-year growth < 0.015 (2 consecutive prints). Base case rests on mid-single-digit growth as incretin volume offsets LOE. Growth falling below the Base/Pipeline-Setback midpoint for two quarters signals the offset is failing.
• Non-GAAP operating margin < 0.48 (2 consecutive prints). Base op margin is 0.509. A print below the Pipeline-Setback level for two quarters indicates the manufacturing build is not being absorbed and fixed cost is de-levering.
• Tirzepatide-franchise net revenue growth < 0.0 (2 consecutive prints). The thesis concentrates on the incretin franchise. Two quarters of outright decline in the lead franchise would confirm competitive or reimbursement erosion rather than a supply-timing effect.
• Capex as a share of revenue > 0.13 (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
• Late-stage pipeline read-out outcome == failure (single event). A pivotal Phase-3 miss on a key incretin or Alzheimer's programme removes an indication-expansion leg that the Growth and Bull paths depend on, forcing a re-rate toward the setback case.

Fact / Inference / Speculation

• FACT: Spot $1,247; 52-week range $619–$1,280; engine rating SELL; house target $1,126 (-10%). (source: Alpha Vantage 2026-08-24, 25 August 2026)
• INFERENCE: Triangulated FV $977 (-22% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits below the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that the market keeps paying the current multiple through the capex cycle — a regime call the engine cannot verify from fundamentals alone.

Conviction Score

Research Conviction measures the strength and quality of the research setup — input coverage, financial quality, valuation support, process agreement. It is NOT the probability that the recommendation succeeds; the forecast track record section is the evidence on that.

66.5/100 (confidence band 54.0–79.0), 81st percentile of 858 covered names (as of 2026-08-24). Weighted composite under config ros-1.19.0 — every component and its inputs below.

Missing inputs (macro tailwinds) are excluded and the remaining weights renormalised; the confidence band widens accordingly.

Score history: 66.8 → 66.8 → 66.7 → 65.8 → 65.8 → 66.6 → 66.4 → 66.4.

Probability-Weighted Return Profile

Horizon: 1 year — at this horizon CAGR equals total return by definition. Expected values are the probability-weighted sums over the full scenario set below.

The gross expected return is the probability-weighted scenario return (it reconciles to the gross PWEV); the diluted figure applies the SBC share-count charge and matches the published PWEV-based target.

Expected Alpha

Expected return minus the return this name is REQUIRED to deliver for its risk (1-year horizon). Constants are pre-registered (preregistered-static (amendment #2, 2026-07-29); not fitted to MCH outcomes).

A negative expected alpha does not change the rating — it says the expected return does not clear the risk-adjusted hurdle at today's price. Rating mechanics are unchanged by this section.

Probability Cross-Checks

Not authoritative. The scenario probabilities in this report are AUTHORED — a judgement about how the world might go, not a measurement. Nothing below modifies them, the target, the rating or any position size. These checks ask only whether anything outside our own model agrees with us; where it does not, that is information for the reader, not a correction we have quietly applied.

Authored set: 5 scenarios, probabilities summing to 1.0, mean target $1100.43.

Factor Exposures

Cross-sectional percentiles over 858 covered names (style scores sector-demeaned; thematic = return-beta to the theme's proxy ETF). 50 = estate median.

Market interaction: correlation vs SPY +0.28, vs QQQ +0.21 (trailing ~1y daily returns).

Options Intelligence

Preferred structure: Put Debit Spread. The selector reads the equity view (direction) and the volatility surface — nothing here re-prices the chain.

• bearish with cheap options — buy defined-risk downside
• Direction bearish from the overlay conviction/rating (read-only input).
• IV/RV at the 33rd percentile of the cross-section → low vol bucket. This is the measure that selects the structure above: it ranks how rich this name's implied vol is against its own realised vol, relative to other names.
• Reported alongside and not used to select: this name's own ATM IV sits at the 62nd percentile of its own month-end history (decile 7). The two measures disagree here — vol is high for this name by its own history while its options are not unusually rich against its realised vol. Where they diverge, the cross-sectional measure is the one acting.
• IV term structure is in contango (longer-dated richer, slope +5.9pp) — favour longer-dated ownership (LEAPS) or calendars that are long the cheaper front.
• No live-chain Put Debit Spread was priced for this name — shown as the indicated strategy; size against a freshly pulled chain.

IV term structure (contango, slope +5.9pp): 32-DTE 33% · 88-DTE 37% · 389-DTE 39%

No live-chain Put Debit Spread was priced for this name — shown as the indicated approach; size against a fresh chain.

Alternatives: Protective Put. IV rank shown via the name's own monthly IV history (advisory); structure selected on the cross-sectional IV/RV percentile. Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Position Sizing Framework

research rating is SELL-tier — the model carries no long position.

Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Options Overlay

A defined-risk way to express the SELL equity view. Chain as of 2026-08-24 — end-of-day marks — indicative, not executable quotes.

Market signals — ATM IV 32.7% (moderate regime) · expected move ±7.6% (2026-09-25) · put/call OI 1.28 · ATM Δ 0.54 / Θ -0.83 / ν 1.47. Direction: NEUTRAL (implied return -21.7% to triangulated fair value $976.59).

Covered Call (if held) (Income / neutral) — Short 1335 C · 2026-09-25 · premium $16.95 · yield 1.4% · priced from the listed chain (EOD marks)

Converts a near-fair holding into income by agreeing to sell at a higher strike — worth weighing when upside looks limited near fair value and being called away is acceptable. Illustrative — no outcome is implied or guaranteed.

Put Spread (income) (Income / would-own) — Short 1145 P / Long 1060 P · 2026-10-02 · net $9.6 · net entry $1,135.40 · yield 0.8% · RoR 13.0% · max loss $75.40 · priced from the listed chain (EOD marks)

Gets paid to wait for a lower entry, with the tail capped: the sold put collects premium while the cheaper long wing below it caps the maximum loss at the spread width — a defined-risk alternative to a naked cash-secured put.

Protective Collar (if held) (Hedge) — Long 1120 P / Short 1380 C · 2027-03-19 · net $25.7 · floor -10.0% · cap +11.0% · priced from the listed chain (EOD marks)

For a holder who wants to stay invested but cap risk: the sold call funds most of the protective put, fencing the position into a band — a way to ride out a de-rating without selling.

Indicative options structures — a defined-risk expression of the equity view, model-and-market illustrated from the last-close chain. NOT personalised advice or an executable quote; premiums, IV and greeks move intraday. Options carry the risk of total loss of premium. Not a registered financial adviser.

Rating Bridge

Rating = SELL because:

• Probability-weighted scenario value implies -12% vs spot
• Monte Carlo median implies -18% vs spot
• DCF fair value implies -30% vs spot — but this is terminal-value sensitive (exit-multiple $871 vs Gordon $612, 30% apart), so it carries less weight
• Bear case (Structural — Patent Cliff (LOE) / IRA Pricing Erosion) downside is -60% vs spot
• Net: the valuation anchor itself sits 21.7% below spot, so there is no reward leg to weigh against the bear case and the reward-to-risk ratio is withheld rather than computed off a negative upside. The rating warrants a Sell.

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 6% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.5% · Σ PV(FCF) $142B + PV(terminal) $677B = EV $819B; − net debt $38.2B → equity $780B ÷ diluted shares $0.90B = $871/share (exit-multiple terminal).

• Gordon terminal at 2.5% → $612/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 15% vs WACC 8.5% → above WACC — the build is value-creative.

Peer set

Implied prices at the peer medians: EV/Rev → $297 (no P/E-implied price — no forward-EPS basis at the peer step).

Weighted fair-value math

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Revenue CAGR ±3pp (250.0); Terminal × ±15% (227.0); Op margin ±3pp (102.0); WACC ±1pp (78.0); Capex intensity ±15% (65.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Research Provenance

Load-Bearing Assumptions

DCF: WACC 8.5%, terminal multiple 26×, FY+5 revenue $85B. Triangulation leans 47% on DCF, 33% on PWEV, 20% on the Monte Carlo median.